MEDIFOCUS INCORPORATED (OTCMKTS:MDFZF)’s Stock Is Buy After Less Market Selling

February 15, 2018 - By Dolores Ford

The stock of MEDIFOCUS INCORPORATED (OTCMKTS:MDFZF) registered a decrease of 43.48% in short interest. MDFZF’s total short interest was 3,900 shares in February as published by FINRA. Its down 43.48% from 6,900 shares, reported previously. With 31,900 shares average volume, it will take short sellers 0 days to cover their MDFZF’s short positions.

It closed at $0.0342 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company has market cap of $6.33 million. The firm owns technology platforms, including Endo-thermotherapy platform, a catheter focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It currently has negative earnings. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia.

More important recent Medifocus Inc. (OTCMKTS:MDFZF) news were published by: Marketwatch.com which released: “Medifocus Inc.” on June 08, 2016, also Businesswire.com published article titled: “Research and Markets: Leading 100 Medical Devices Companies of USA/Canada 2015”, Digitaljournal.com published: “Medifocus, Inc. Expands Its Reach into the Israeli Market with Amos Gazit Ltd …” on January 09, 2018. More interesting news about Medifocus Inc. (OTCMKTS:MDFZF) was released by: Businesswire.com and their article: “PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors” with publication date: October 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: